Pacira BioSciences, Inc. (PCRX)
USD 26.27
(14.67%)
USD 26.27
(14.67%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 104.35 Million USD | 8.63% |
| 2022 | 96.06 Million USD | -2.52% |
| 2021 | 98.55 Million USD | 52.44% |
| 2020 | 64.65 Million USD | 10.9% |
| 2019 | 58.29 Million USD | 20.03% |
| 2018 | 48.56 Million USD | 17.29% |
| 2017 | 41.41 Million USD | 32.4% |
| 2016 | 31.27 Million USD | -49.26% |
| 2015 | 61.64 Million USD | 110.66% |
| 2014 | 29.26 Million USD | 88.1% |
| 2013 | 15.55 Million USD | 28.82% |
| 2012 | 12.07 Million USD | 870.04% |
| 2011 | 1.24 Million USD | -22.43% |
| 2010 | 1.6 Million USD | -7.17% |
| 2009 | 1.72 Million USD | -14.74% |
| 2008 | 2.02 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 96.78 Million USD | -7.26% |
| 2024 Q2 | 103.43 Million USD | 6.88% |
| 2023 Q1 | 92.97 Million USD | -3.21% |
| 2023 Q3 | 96.52 Million USD | 4.77% |
| 2023 Q2 | 92.13 Million USD | -0.91% |
| 2023 FY | 104.35 Million USD | 8.63% |
| 2023 Q4 | 104.35 Million USD | 8.12% |
| 2022 Q3 | 96.79 Million USD | -3.77% |
| 2022 Q4 | 96.06 Million USD | -0.76% |
| 2022 FY | 96.06 Million USD | -2.52% |
| 2022 Q1 | 103.66 Million USD | 5.19% |
| 2022 Q2 | 100.58 Million USD | -2.97% |
| 2021 Q3 | 67.2 Million USD | 2.98% |
| 2021 FY | 98.55 Million USD | 52.44% |
| 2021 Q1 | 64.6 Million USD | -0.07% |
| 2021 Q4 | 98.55 Million USD | 46.63% |
| 2021 Q2 | 65.26 Million USD | 1.02% |
| 2020 Q1 | 59.66 Million USD | 2.35% |
| 2020 Q2 | 66.69 Million USD | 11.77% |
| 2020 Q3 | 68.54 Million USD | 2.78% |
| 2020 Q4 | 64.65 Million USD | -5.68% |
| 2020 FY | 64.65 Million USD | 10.9% |
| 2019 Q3 | 60.23 Million USD | 14.31% |
| 2019 Q4 | 58.29 Million USD | -3.22% |
| 2019 Q2 | 52.69 Million USD | 12.05% |
| 2019 Q1 | 47.02 Million USD | -3.17% |
| 2019 FY | 58.29 Million USD | 20.03% |
| 2018 Q4 | 48.56 Million USD | 8.21% |
| 2018 FY | 48.56 Million USD | 17.29% |
| 2018 Q3 | 44.88 Million USD | 6.73% |
| 2018 Q2 | 42.05 Million USD | 5.02% |
| 2018 Q1 | 40.04 Million USD | -3.3% |
| 2017 Q2 | 33.6 Million USD | 10.86% |
| 2017 Q1 | 30.31 Million USD | -3.09% |
| 2017 Q3 | 39.11 Million USD | 16.4% |
| 2017 FY | 41.41 Million USD | 32.4% |
| 2017 Q4 | 41.41 Million USD | 5.88% |
| 2016 FY | 31.27 Million USD | -49.26% |
| 2016 Q1 | 63.74 Million USD | 3.4% |
| 2016 Q3 | 37.47 Million USD | -38.48% |
| 2016 Q4 | 31.27 Million USD | -16.54% |
| 2016 Q2 | 60.91 Million USD | -4.44% |
| 2015 Q1 | 36.26 Million USD | 23.92% |
| 2015 Q4 | 61.64 Million USD | 9.82% |
| 2015 FY | 61.64 Million USD | 110.66% |
| 2015 Q2 | 48.76 Million USD | 34.48% |
| 2015 Q3 | 56.13 Million USD | 15.1% |
| 2014 Q2 | 19.19 Million USD | 24.93% |
| 2014 Q4 | 29.26 Million USD | 23.67% |
| 2014 Q1 | 15.36 Million USD | -1.24% |
| 2014 FY | 29.26 Million USD | 88.1% |
| 2014 Q3 | 23.66 Million USD | 23.28% |
| 2013 Q4 | 15.55 Million USD | -0.31% |
| 2013 FY | 15.55 Million USD | 28.82% |
| 2013 Q3 | 15.6 Million USD | 9.74% |
| 2013 Q2 | 14.22 Million USD | 32.17% |
| 2013 Q1 | 10.76 Million USD | -10.91% |
| 2012 Q4 | 12.07 Million USD | 1.44% |
| 2012 Q1 | 5.07 Million USD | 307.87% |
| 2012 FY | 12.07 Million USD | 870.04% |
| 2012 Q2 | 9.29 Million USD | 83.12% |
| 2012 Q3 | 11.9 Million USD | 28.04% |
| 2011 Q4 | 1.24 Million USD | -25.31% |
| 2011 Q2 | 1.88 Million USD | 5.96% |
| 2011 Q1 | 1.77 Million USD | 10.78% |
| 2011 Q3 | 1.66 Million USD | -11.52% |
| 2011 FY | 1.24 Million USD | -22.43% |
| 2010 Q3 | 1.05 Million USD | -12.35% |
| 2010 FY | 1.6 Million USD | -7.17% |
| 2010 Q4 | 1.6 Million USD | 52.86% |
| 2010 Q2 | 1.19 Million USD | 0.0% |
| 2009 FY | 1.72 Million USD | -14.74% |
| 2009 Q4 | 1.72 Million USD | 0.0% |
| 2008 FY | 2.02 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Journey Medical Corporation | 10.2 Million USD | -922.467% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 6.154% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -1441.631% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1719.659% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1719.659% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Safety Shot Inc | 1.86 Million USD | -5481.428% |
| Alpha Teknova, Inc. | 11.59 Million USD | -800.06% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | -222.755% |
| Bright Green Corporation | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | -95.821% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -59.019% |
| Cosmos Health Inc. | 4.78 Million USD | -2078.99% |
| PainReform Ltd. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -12786.953% |
| Embecta Corp. | 152.1 Million USD | 31.392% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | -795.965% |
| Procaps Group, S.A. | 96.83 Million USD | -7.766% |
| Theratechnologies Inc. | 6.06 Million USD | -1620.293% |
| Harrow Health, Inc. | 10.86 Million USD | -860.274% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -3737.918% |
| Biofrontera Inc. | 10.9 Million USD | -856.665% |
| DURECT Corporation | 2.21 Million USD | -4602.704% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -34.809% |
| Cronos Group Inc. | 30.33 Million USD | -243.957% |
| OptiNose, Inc. | 8.05 Million USD | -1195.989% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -10435299900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -1731.065% |
| Organogenesis Holdings Inc. | 28.25 Million USD | -269.352% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -3797.969% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -2163.936% |
| Radius Health, Inc. | 278.64 Million USD | 62.549% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -3021.289% |
| ProPhase Labs, Inc. | 3.84 Million USD | -2616.819% |
| Phibro Animal Health Corporation | 265.91 Million USD | 60.756% |
| Procaps Group S.A. | 96.83 Million USD | -7.766% |
| Alvotech | 74.43 Million USD | -40.197% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 96.992% |
| Rockwell Medical, Inc. | 5.87 Million USD | -1677.431% |
| Aytu BioPharma, Inc. | 12.63 Million USD | -726.035% |
| SIGA Technologies, Inc. | 64.21 Million USD | -62.497% |
| Tilray Brands, Inc. | 252.08 Million USD | 58.604% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | -161.02% |
| Shineco, Inc. | 1.58 Million USD | -6469.176% |
| PetIQ, Inc. | 159.3 Million USD | 34.496% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 68403.682% |
| Incannex Healthcare Limited | -10.01 Million USD | 1141.967% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -172.462% |
| Alimera Sciences, Inc. | 1.87 Million USD | -5453.646% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | -176.901% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -6379.979% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -2227.749% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -40927.002% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -905.328% |
| Hempacco Co., Inc. | 2.54 Million USD | -4004.139% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | -40.197% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | -118.339% |
| Lantheus Holdings, Inc. | 64.02 Million USD | -62.978% |
| Currenc Group, Inc. | 732.91 Thousand USD | -14138.154% |
| Kamada Ltd. | 87.74 Million USD | -18.925% |
| Indivior PLC | 141.79 Million USD | 26.408% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -21557.189% |
| Flora Growth Corp. | 8.5 Million USD | -1126.528% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -40927.002% |
| Evolus, Inc. | 10.99 Million USD | -848.836% |
| HUTCHMED (China) Limited | 50.25 Million USD | -107.635% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 1.398% |
| Akanda Corp. | 1.28 Million USD | -8008.904% |